Prosonix, Mylan in generic respiratory deal

Prosonix Ltd. (Oxford, U.K.) granted Mylan Inc. (NASDAQ:MYL) rights to market generic versions of asthma product Flixotide/ Flovent from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in several regions, including the U.S., EU, Canada and Japan. Prosonix's generics -- PSX1001 and PSX1050 -- are formulations of fluticasone monotherapy in pressurized metered dose inhalers. Prosonix plans to submit an MAA to EMA for PSX1001 this year based on in vitro equivalence data. PSX1050 is the same formulation of fluticasone as PSX1001 but the inhaler includes a dose counter. Prosonix and Mylan aren't disclosing further details. GSK reported L796 million ($1.3 billion) in 2013 worldwide sales of Flixotide/Flovent. ...